Novo Nordisk A/S NVO
Annual
Quarterly
No annual revenue total was found in NOVO NORDISK A/S's SEC filings.
Novo Nordisk A/S (NVO) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
4.44B
+0.1% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NVO (NYSE), NONOF (OTC)
- Fiscal year ends
- December 31
- Headquarters
- Bagsvaerd Denmark, Denmark
- SEC filer status
- Large accelerated filer
- SEC CIK
- 353278
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Pfizer Inc PFE
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Nov 4, 2026 | Sep 30, 2026 |
| 6-K | Current report (foreign issuer) | Nov 3, 2026 | Nov 3, 2026 |
| 6-K | Current report (foreign issuer) | Oct 26, 2026 | Oct 26, 2026 |
| 6-K | Current report (foreign issuer) | Oct 19, 2026 | Oct 19, 2026 |
| 6-K | Current report (foreign issuer) | Oct 13, 2026 | Oct 12, 2023 |
| 6-K | Current report (foreign issuer) | Oct 6, 2026 | Oct 5, 2026 |
All 1001 Novo Nordisk A/S SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.